A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAIVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
- Registry ID
- C6461016
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- PFIZER CANADA ULC
- Last update
- 2026-03-12
Conditions
- GASTROESOPHAGEAL ADENOCARCINOMA
Related clinical trials
- AACR ADAPTIVE BIOMARKER-DRIVEN ORGAN PRESERVATION TRIAL IN GASTROESOPHAGEAL ADENOCARCINOMAS
- ROSETTA GASTRIC-204: A BLINDED, RANDOMIZED, PHASE 2/3 STUDY OF PUMITAMIG IN COMBINATION WITH CHEMOTHERAPY VERSUS NIVOLUMAB IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
- A PHASE III, MULTICENTRE, RANDOMISED CONTROLLED STUDY OF SONESITATUG VEDOTIN IN
COMBINATION WITH FLUOROPYRIMIDINE WITH OR WITHOUT RILVEGOSTOMIG IN FIRST-LINE
CLAUDIN18.2-POSITIVE, HER2-NEGATIVE, ADVANCED/METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
(CLARITY-GASTRIC 02)
- A MASTER PROTOCOL FOR AN OPEN-LABEL, MULTI-DRUG, MULTI-CENTER,
PHASE II PLATFORM STUDY TO EVALUATE THE SAFETY, TOLERABILITY,
PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF NOVEL
AGENTS OR COMBINATIONS AS PERIOPERATIVE TREATMENT IN PARTICIPANTS
WITH LOCALLY ADVANCED RESECTABLE GASTROESOPHAGEAL
ADENOCARCINOMA (GEMINI-PERIOP GC)
- A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY
AND SAFETY OF MK-2870 VERSUS TREATMENT OF PHYSICIAN¿S CHOICE IN 3L+
ADVANCED/METASTATIC GASTROESOPHAGEAL ADENOCARCINOMA (GASTRIC
ADENOCARCINOMA, GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, AND ESOPHAGEAL
ADENOCARCINOMA)
- PHASE 2 STUDY OF ZW25 PLUS FIRST-LINE COMBINATION CHEMOTHERAPY IN HER2-EXPRESSING GASTROESOPHAGEAL ADENOCARCINOMA (GEA)
View on source registry